Back

Long-term effects of mavacamten treatment in obstructive hypertrophic cardiomyopathy (HCM): updated cumulative analysis of the EXPLORER cohort of MAVA-long-term extension (LTE) study up to 120 weeks

27 August 2023 (10:15 - 10:25)
Organised by: Logo
Congress Presentation Part of: Contemporary management of hypertrophic cardiomyopathy Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Pablo Garcia-Pavia

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Spain)

5 More presentations in this session

Presentation thumbnail
Sacubitril/valsartan for treatment of symptomatic non-obstructive hypertrophic cardiomyopathy: a randomised, controlled, phase II clinical trial (SILICOFCM)
Doctor M. Tafelmeier (Regensburg, DE)
Abstract Slides Video
Presentation thumbnail
Efficacy of cardiac myosin inhibitors for obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials
Ms N. Felix (Sao Paulo, BR)
Abstract Slides Video
Presentation thumbnail
Long term outcome after septal reduction therapies in patients with hypertrophic cardiomyopathy: insights from the SHaRe registry
Doctor N. Maurizi (Lausanne, CH)
Abstract Slides Video
Presentation thumbnail
Outcomes in patients with hypertrophic cardiomyopathy developing left ventricular systolic dysfunction after septal reduction therapy
Miss D. Hiestand (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
The efficacy and safety of direct oral anticoagulants compared with vitamin K antagonist in patients with hypertrophic cardiomyopathy and atrial fibrillation: a systematic review and meta-analysis
Miss S. Lyu (Beijing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Contemporary management of hypertrophic cardiomyopathy
Video

The Event

Event poster

ESC Congress 2023

27 August 2023 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Long-term safety and efficacy of mavacamten in obstructive hypertrophic cardiomyopathy: up to 3.5-year follow-up results of the EXPLORER cohort of MAVA-Long-Term Extension study
thumbnail
Congress Presentation
Long-term efficacy of mavacamten on health status in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: results from long-term extension of the EXPLORER-CN trial
thumbnail
Congress Presentation
Spotlight on cardiac myosin inhibition

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources